Skip to content

Evaluation of safety and efficacy of Poly herbal formulations in the management of Psoriasis

A Randomized Controlled Trial (RCT) to Evaluate Safety and Efficacy of Compound Unani Formulations Nuqooe Musaffi Orally and Marhame Surkh Topically in the Management of Taqashshur al Jild (Psoriasis). - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094098
Enrollment
44
Registered
2025-09-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Orally Nuqooe Musaffi along with local application of Marham Surkh which contains following ingredients 1. Murdarsang (Litharge) 2. Haldi (Curcuma longa) 3. Roghane zaitoon (Olea europ

Sponsors

Hakim Syed Zia ul Hasan Government Autonomous Unani Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of psoriasis. 2. Patients with PASI Score less than 10. 6. Patients who are willing and able to comply with the protocol. 4. Patients who are willing and capable of providing a signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2. Patients of pustular psoriasis, erytherodermic psoriasis and psoriatic arthritis. 3. Patients with history of local and systemic corticosteroids, immunosuppressive drugs and anti psoriatic systemic therapies during last 4 weeks. 4. Patients with uncontrollable significant diseases like DM,Hypertension, renal failure, hepatic failure and cardiac comorbidities. 5. Patients suffering from other concomitant skin diseases like vitiligo,eczema, lichen simplex and seborrheic dermatitis etc. 6. Patients concurrently participating in any other clinical trial.

Design outcomes

Primary

MeasureTime frame
1. Psoriasis Area Severity Index (PASI) 2. Itching Visual Analogue Scale (VAS) (On a 10 cm long horizontal scale)Timepoint: 1. Psoriasis Area Severity Index (PASI) at Baseline and Final visit 2. Itching Visual Analogue Scale (VAS) at day 1,14,28,42

Secondary

MeasureTime frame
Dermatology Life Quality Index (DLQI)Timepoint: On day 1,14,28,42

Countries

India

Contacts

Public ContactBushra Ansari

Hakim Syed Zia ul Hasan Government Autonomous Unani Medical College and Hospital

dilshadali28@gmail.com08319768281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026